NICE's final guidance on prostate cancer diagnosis and treatment, published this week, states that 'men with low-risk, localised prostate cancer who are considered suitable for radical treatment should first be offered active surveillance'.
Dr Heather Payne, an oncologist from University College Hospital, London, said: 'Currently, most active surveillance is done in secondary care, but more prostate cancer care will be moving into primary care.
'GPs will be doing active surveillance. This involves measuring PSA levels every three months to check to see how prostate cancer is progressing in men diagnosed with early localised prostate cancer.
'This allows you to delay radical treatment thus reducing the chances of side-effects.'
NICE have also issued smoking cessation guidance advising nicotine replacement therapy, varenidine or bupropion as treatments.